Belinostat

Belinostat (PXD101; PX105684) is a potent HDAC inhibitor with an IC50 of 27 nM in HeLa cell extracts.

Product Specifications

CAS Number

[866323-14-0]

Product Name Alternative

PXD101; PX105684

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; HDAC

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Belinostat.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic) |Ethanol : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(NC1=CC=CC=C1)(C2=CC(/C=C/C(NO)=O)=CC=C2)=O

Molecular Formula

C15H14N2O4S

Molecular Weight

318.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histonedeacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2 (8) :721-8.|[2]Qian X, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5 (8) :2086-95.|[3]Chia S, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8 (1) :435.